Aller au contenu principal
2019 article

Rectal Diclofenac administration for prevention of post-Endoscopic Retrograde Cholangio-Pancreatography (ERCP) acute pancreatitis. Randomized prospective study: doi: 10.7417/CT.2019.2156

0Citations signalées, ce qui n’est pas une note de qualité
2Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : it. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

IntroductionPost-Endoscopic Retrograde Cholangio-Pancreatography pancreatitis (PEP) is a relevant (1-4%) complication of biliopancreatic operative endoscopy. Rectal nonsteroidal anti-inflammatory drugs (specifically, 100 mg of diclofenac) have shown promising prophylactic activity in PEP. The aim of our prospective study is to report whether prophylactic oral versus rectal suppository versus intramuscular diclofenac versus placebo are able to reduce the incidence and the severity of ERCP-induced pancreatitis. Materials and MethodsIn this randomized, double-blinded, prospective study, 100 patients (49 male, 51 female), similar with regard to indication for ERCP, were enrolled between January 2016 and November 2017 to undergo ERCP in the Section of General and Thoracic Surgery of University Hospital of Palermo. They were randomized into five groups, respectively 20 patients with placebo by mouth; 20 patients with 50 mg diclofenac sodium enteric-coated capsules by mouth; 20 with 100 mg rectal suppository diclofenac, 20 with 75 mg/3 ml intramuscular diclofenac sodium, 20 with 75 mg/3 ml intramuscular diclofenac sodium and 20 with 75 mg/3 ml intravenous diclofenac. All drugs were administered 30 to 90 minutes before ERCP. All clinical data were collected one day before and 2, 12 and 24 hour after ERCP. ResultsData were prospectively collected and to demonstrate the preventive effect of rectal diclofenac on PEP, a two-by-two table and chi-square test with Yates correction were used: the incidence of PEP was significantly lower (p < 0.001) in the rectal diclofenac group respect to other groups and, in the same way, the incidence of post- ERCP pain was significantly lower in the rectal diclofenac group than in the other groups (p = 0.001) and patients discharge was consequently earlier (p < 0.01). Conclusions100 mg dose rectal diclofenac administered 30-60 minutes before ERCP can effectively prevent PEP

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

Aucun DOI disponible pour le contrôle Crossref.

Où se fait cette recherche

  • Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo pays non établi dans la notice
    Établissement de santé
  • University of Palermo pays non établi dans la notice
    Université ou école supérieure
  • University Teaching Hospital Paolo Giaccone of Palermo pays non établi dans la notice
    Université ou école supérieure

Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo, University of Palermo et University Teaching Hospital Paolo Giaccone of Palermo.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Gallbladder and Bile Duct DisordersLiver Diseases and ImmunityInflammatory mediators and NSAID effects

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.